CMS Assigns Permanent J-Code for Omeros' YARTEMLEA, Streamlining Reimbursement
Event summary
- CMS assigned a permanent HCPCS J-code (J1289) for YARTEMLEA, effective July 1, 2026.
- The J-code simplifies billing and reimbursement for Medicare and commercial payers.
- YARTEMLEA is the only approved treatment for TA-TMA, a severe complication of stem cell transplants.
- Omeros' YARTEMLEAssist program supports patient and provider access to the drug.
The big picture
The permanent J-code for YARTEMLEA removes a key barrier to access, aligning with broader trends in value-based healthcare and streamlined reimbursement. With approximately 30,000 allogeneic transplants annually in the U.S. and Europe, and TA-TMA affecting up to 56% of recipients, this development positions Omeros to capture significant market share in a high-mortality indication. The pending EMA decision could further amplify its strategic footprint.
What we're watching
- Commercialization Pace
- How quickly the permanent J-code accelerates YARTEMLEA's adoption among providers and payers.
- Regulatory Milestones
- Whether the EMA approves YARTEMLEA for TA-TMA in mid-2026, expanding its market reach.
- Competitive Positioning
- The extent to which Omeros can maintain exclusivity in treating TA-TMA amid potential future therapies.
Related topics